Changes to the Roche Enlarged Corporate Executive Committee

Basel, 23 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Nina Schwab-Hautzinger (1975) has been appointed Head of Group Communications and a member of the enlarged Corporate Executive Committee effective 1 February 2026. Nina Schwab-Hautzinger rejoins Roche from her role at BASF as Head of Corporate Communications and Government Relations. During her previous thirteen year tenure at Roche, Nina Schwab-Hautzinger held various communications leadership roles such as Head of Corporate Brand & Communications at the Group level and Head of Communications & Public Affairs for Pharma in Germany.  She has also led the healthcare practice in a strategic communications consultancy in Singapore. Nina Schwab-Hautzinger studied at the University of Mannheim, Germany and the University of Waterloo, Canada. She received her doctorate from the University of Zurich, Switzerland, Department of Communication and Media Research. Roche’s CEO Thomas Schinecker: “I am pleased to announce that Nina Schwab-Hautzinger will be returning to Roche as Head of Group Communications and will join Roche’s executive leadership team. In today’s rapidly evolving world, clear and impactful communication is a critical success factor both internally and externally for any company. Nina’s extensive expertise, expansive network, and her experience across global, regional, and local contexts will be instrumental in advancing our long-term strategic ambitions. I would like to thank the current Head of Group Communications, Barbara Schaedler, for staying on longer to ensure a smooth hand-over."  About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: media.relations@roche.com Hans Trees, PhD Phone: +41 79 407 72 58 Sileia Urech Phone: +41 79 935 81 48 Nathalie Altermatt Phone: +41 79 771 05 25 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +49 172 6367262 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03   Attachment Media Release Changes to Enlarged CEC English Weiter zum vollständigen Artikel bei Roche Holding AG Weiter zum vollständigen Artikel bei Roche Holding AG